Lyra Therapeutics, Inc. (LYRA) Stock Forecast
LYRA analyst forecast
as of October 21, 2026- Analyst consensus
- Hold 3.00 / 5 from 4 analysts
- Price target
- $16.00 average of analyst targets
- Upside to target
- +8,321.1% from the latest close
- Next earnings
- —
- 52-week range
- $0.03 – $0.20
LYRA analyst ratings
4 analystsNumber of analysts at each rating.
LYRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LYRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$7.02 | −$7.02 | −$7.02 | −$25.66 | +72.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LYRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $700,000 | $700,000 | $700,000 | −5.1% | 1 |
LYRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LYRA revenue: reported and forecast
LYRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$9.59 | −$4.76 | −$4.76 | −$4.00 | −$7.02 | −26.8% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LYRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LYRA beat in 7 of 11.
What analysts expect from LYRA
4 analysts cover Lyra Therapeutics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.00, 8,321.1% above the latest close of $0.19. For 2026 the average estimate is −$7.02 per share on revenue of $0.7 million. Lyra Therapeutics beat the EPS estimate in 7 of the last 11 quarters.
Related: LYRA income statement, LYRA key metrics, LYRA chart. See the LYRA stock overview for the latest quote and news.
LYRA forecast FAQ
What is Lyra Therapeutics's price target?
The average analyst price target for Lyra Therapeutics is $16.00, 8,321.1% above the latest close of $0.19.
Is Lyra Therapeutics a buy, hold or sell?
Of 4 analysts covering Lyra Therapeutics, 0 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
Does Lyra Therapeutics usually beat earnings estimates?
Lyra Therapeutics reported EPS at or above the analyst estimate in 7 of the last 11 quarters.